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We report on two substance misusers with depression resistant to
tricyclic antidepressant treatment who responded to triiodothyronine
augmentation. The management of resistant depression, augmentation
strategies with particular reference to triiodothyronine, and the
possible mechanism of action of triiodothyronine are discussed.
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Introduction
Depression is a common condition—the National Comorbidity Survey in
the US found a lifetime prevalence of 17% for major depression.1 Annually,
approximately 3% of the general population in the UK receive treat-
ment for depression from their general practitioners.2 Despite the well-
established efficacy of antidepressants in the treatment of depression,
approximately 30% of patients fail to respond to tricyclic antidepressants
(TCAs) or selective serotonin reuptake inhibitors.3
Potentiation of antidepressant effects by L-triiodothyronine (T3)
in tricyclic nonresponders was first reported by Prange et al in 1969.4
L-triiodothyronine augmentation, however, has remained relatively
underused locally and in other countries. A survey in the UK found that
the T3 augmentation strategy has rarely been used among resistant
depression.5 A similar scenario exists locally, as revealed from the
questionnaire survey among Hong Kong psychiatric trainees.6 One of
the reasons for the underutilisation of T3 augmentation is the lack
of experience among psychiatrists. Thus, while reports in the literature
have shown the usefulness of the strategy, it has rarely been applied in
clinical practice.
No reports of T3 augmentation were found in the Hong Kong
Medical Journal or the Hong Kong Journal of Psychiatry during
the past 10 years. We report here two cases of depression resistant
to TCA treatment—both patients were substance misusers who
responded to T3 augmentation.
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Case reports
Case 1
A 22-year-old Chinese single unemployed woman first
presented in December 1995 with visual and audi-
tory hallucination for 4 months. Her mood was not
depressed at that time. She drank a bottle of cough
mixture a day and had been dependent on it since she
was 17 years old. She also used cannabis and benzodia-
zepines occasionally. She was diagnosed with drug-
induced psychosis. She was prescribed thioridazine
50 mg/d for 3 months and her psychotic symptoms
gradually subsided.
The patient was admitted to Queen Mary Hospital
in September 1998 when she presented with restless-
ness, agitation, disorientation, and irrelevant speech
for 2 days. She had been misusing methamphetamine
intermittently since July 1997, when she gradually
stopped using cough mixture. Urine toxicology on
admission showed amphetamine and a diagnosis of
amphetamine intoxication was made. She made a
spontaneous recovery 3 days after admission, but, she
became severely depressed with frequent weeping
episodes, loss of interest, insomnia, decreased appetite,
sense of worthlessness, and guilt feelings with self-
blame. Amitriptyline was started at an increased dose
of 200 mg/d for 8 weeks. She failed to respond, how-
ever, and haloperidol up to 8 mg/d was added for
2 weeks but was stopped when there was no sign of
significant improvement. Investigation results were
unremarkable except for a persistent low free thyroxine
(T4) of 0.9 pmol/L (normal range, 10-36 pmol/L) with
normal thyroid-stimulating hormone (TSH) level and
elevated anti-thyroglobulin. She was clinically euthy-
roid. While amitriptyline was maintained at 200 mg/d,
T3 augmentation was started with an initial dose of
20 µg for 5 weeks, and then increased to 40 µg. Her
mood improved after 1 week of T3 augmentation and
she experienced complete remission 6 weeks later.
At discharge, she was cheerful with no further depres-
sive symptoms. L-triiodothyronine was maintained for
another 2 months before tapering of the dose.
Case 2
An 18-year-old Chinese single unemployed man had
been a polysubstance misuser since the age of 13 years.
He first experimented with cannabis, then quickly
graduated to daily use of methamphetamine by fume
inhalation. At the age of 15 years, he stopped using
methamphetamine and started taking heroin. He became
dependent on heroin and used up to one tablet per day.
The diagnosis of depression was first made at the
age of 16 years when he presented with loss of interest,
decreased energy, loss of confidence, poor concen-
tration, recurrent suicidal ideas, insomnia, and loss
of appetite for the previous 2 months. At that time he
was misusing heroin only and the pattern of its use
apparently had no relationship to his depressed mood.
He was admitted twice for detoxification and treat-
ment of depression in November 1998 and June 1999.
His depression responded partially to dothiepin
150 mg/d and he had mild depressive symptoms in
between treatment episodes. His drug compliance was
good.
His mood deteriorated again in September 1999.
This mood change was apparently precipitated by
the tense family relationship he experienced as a result
of his continued use of heroin. An attempt was made
to further increase the dose of dothiepin but he could
not tolerate the feelings of sedation and dizziness.
After detoxification with methadone replacement, he
remained depressed with similar symptoms to those
he previously experienced. All investigations includ-
ing thyroid function test were normal. Subsequently,
T3 augmentation was started with T3 20 µg/d and
increasing to 40 µg/d for 10 days. The dothiepin dose
remained at 150 mg/d. Some improvement in mood
was noted 3 days after T3 augmentation. After 2
weeks, he had no more episodes of crying and his
energy and interest recovered. He participated actively
in ward activities and began to plan his future. L-
triiodothyronine was reduced 2 months later and he
remained euthymic and abstained from heroin.
Discussion
When patients do not respond to an adequate trial
of a TCA, drug compliance should be checked, the
diagnosis reviewed, and any perpetuating factors,
such as important stressors should not be overlooked.
For the true nonresponders, treatment options include
switching to another antidepressant, electroconvulsive
therapy, or using an augmentation strategy. Whether
to switch antidepressants or to augment depends on
the severity of illness and the side-effects of the current
medication. Switching to another antidepressant
has the advantage of keeping the treatment simple and
thus helps to improve compliance. Augmentation often
produces a more rapid onset of action, however. This
approach may also help to improve the initial response
of the first agent or add other beneficial effects to the
original regimen.7
Of all the augmentation strategies, lithium
augmentation has received the most attention. There
has been increasing evidence of the effectiveness of
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T3 augmentation, however. In 1982, Goodwin et al8
performed the first double-blind study reporting the
efficacy of T3 in converting TCA nonresponders to
responders. A recent meta-analysis has reported that
depressed patients resistant to treatment given T3
augmentation were two-fold more likely to respond
than non-augmented controls.9 Systematic comparison
of T3 and lithium found that each was effective in
approximately two thirds of TCA nonresponders. It
remains impossible, however, to predict which patients
will respond better to T3 or lithium augmentation.
Joffe10 reported that patients who did respond to
the addition of T3 were less likely to benefit from
adjunctive lithium and vice versa.
The usual dose of T3 in augmentation therapy is
25 µg/d to 50 µg/d. A starting dose of 20 µg increas-
ing to 40 µg was given to the patients in this study.
Initial improvement in mood is usually apparent within
several days. Goodwin et al8 reported that there was
improvement in all aspects of the depressive syndrome
within 1 to 3 days. For the two patients in this study,
initial responses were noted after 3 and 7 days. An
adequate trial of T3 augmentation should last for 7
to 14 days to reach its full effect. If T3 augmentation
is effective, most studies recommend a maintenance
period of 2 months before gradually reducing the dose
at the rate of 10 µg every 3 to 7 days.
L-triiodothyronine augmentation therapy should not
be used in the presence of endocrine disorders such as
hyperthyroidism, uncorrected adrenal insufficiency,
and phaeochromocytoma. It is also contraindicated for
patients with cardiac disease, angina, acute myocardial
infarction, or hypertension. Adverse reactions are
uncommon if daily doses do not exceed 50 µg. The
two patients reported here did not have any side-effects.
While receiving treatment, patients should be moni-
tored for signs and symptoms of thyrotoxicosis.
The two cases illustrated here show a common
feature. Both subjects were substance misusers and yet
they responded to T3 augmentation. This suggests that
T3 augmentation can be helpful in resistant depression
regardless of the aetiology of the illness. We are not
aware of any study specifically conducted on the
efficacy of T3 augmentation among substance misusers.
Mood disturbances, in particular depression, however,
are common among substance misusers, especially for
those who misuse stimulants such as methamphetamine
or cocaine. The two patients reported here had a history
of methamphetamine misuse. Although the psychiatric
symptomatology of most substance misusers tends
to fluctuate over time, the two patients were observed
to have persistent depression in an in-patient setting,
and the depressive symptoms mitigated with T3
augmentation. The aetiology of depression in substance
misusers is complicated since both psychological
reactions and physical consequences of illicit drug
use may be important. Poor social support, family
relationship problems, unemployment, delinquent
history, and personality problems are common in
substance misusers, as shown for the two reported
patients. As a result, depression in substance misusers
demands a diverse and aggressive treatment approach.
Persistent depression is likely to create difficulties
for rehabilitation among drug misusers. Although this
report focuses on the drug treatment of these patients,
psychosocial approaches should not be overlooked.
The exact mechanism of action of T3 augmentation
remains largely unknown. In depressed patients, the
circulating plasma levels of free T4 appear to be normal,
but levels of free T3 may be decreased. Approximately
one third of depressed patients show blunting of
the TSH response to thyrotropin releasing hormone.
Approximately 15% of depressed patients have
elevated basal TSH levels, probably indicating sub-
clinical hypothyroidism, and thyroid autoantibodies
are found in a similar percentage of patients.11
Thyroid abnormalities are found at a higher frequency
among TCA nonresponders and this may link with
the underlying mechanism of T3 augmentation.
In most case reports, patients had normal thyroid
function, as in our second case. There seems to be no
relationship between thyroid state and the efficacy of
T3 augmentation. In the first case, the patient had sick
euthyroid syndrome, which is sometimes seen in
depressed patients. In this condition, peripheral
deiodination of T4 to T3 is reduced, although the TSH
level is normal.
One proposed mechanism of T3 augmentation
is that T3 may raise peripheral thyroid hormone
concentrations in patients with covert or borderline
hypothyroidism. Other authorities believe that
there is no difference in the thyroid state of the
responders and nonresponders to T3 augmentation.12
L-triiodothyronine may act in euthyroid patients
through augmentation of the β-adrenergic system.13
Alternatively, T3 may also affect thyroid utilisation
and local neuronal deiodination in the brain.
Conclusion
L-triiodothyronine augmentation is effective for
some TCA nonresponders and the evidence from the
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two patients reported here seem to suggest that T3
augmentation works equally well among substance
misusers. It should be remembered, however, that this
report consists of only two patients. Although the
authors are impressed with the clinical improvement,
there is no standardised measure for these changes.
Nevertheless, we believed this treatment strategy
should be used more often in local practice.
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